ALLO News and Press, Allogene Therapeutics Inc. From 08/10/22

Clinical-stage biotech SpringWorks Therapeutics ( NASDAQ: SWTX ) lost ~21% Wednesday, the sharpest intraday decline since May after its partner Allogene ( ALLO ) said that the company’s lead candidate nirogacestat would not be used in dose expansion cohorts in a...

Allogene Therapeutics ( NASDAQ: ALLO ) stock rose ~8% after the company's Q2 results beat analysts' estimates. The company also said that in the coming weeks, it expects to receive clearance from the U.S. Food and Drug Administration (FDA) to start a potential p...

Raymond James has downgraded Allogene ( NASDAQ: ALLO ) Therapeutics from outperform to market perform as the stock price has exceeded the firm's target. Raymond James had a price target of $13. Allogene ( ALLO ) closed on Tuesday at $15.03. Shares are up 7% in ...

Allogene Therapeutics, Inc. (ALLO) Q2 2022 Earnings Conference Call August 9, 2022 5:00 PM ET Company Participants Christine Cassiano – Chief Communications Officer David Chang – President and Chief Executive Officer Rafael Amado – Executive ...

Allogene Therapeutics press release ( NASDAQ: ALLO ): Q2 GAAP EPS of -$0.52 beats by $0.08 . Revenue of $0.09M (+125.0% Y/Y) beats by $0.07M . Ended Second Quarter with $686 Million in Cash, Cash Equivalents and Investments. While the Company anticipates sp...

U.S. FDA Clearance on Potential Pivotal Phase 2 Trial of ALLO-501A Anticipated in Coming Weeks Expected to be the Industry’s First Allogeneic CAR T Phase 2 Pivotal Trial Clearance to Cover ALPHA2 Protocol and Chemistry Manufacturing and Controls (CMC) for Use of ALLO-501A...

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that management plans to participate in t...

SOUTH SAN FRANCISCO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report second quarter 2022 f...

Gainers: NexImmune ( NEXI ) +34% . Allogene Therapeutics ALLO +12% . SOPHiA GENETICS ( SOPH ) +12% . Verona Pharma ( VRNA ) +8% . R1 RCM ( RCM ) +7% . Losers: Codexis ( CDXS ) -43% . 10x Genomics ( TXG ...

Allogene Therapeutics ( NASDAQ: ALLO ) stock rose ~9% premarket July 15 after Goldman Sachs upgrade the stock to Buy from Neutral with a price target of $32, from $9. The SA Quant Rating on ALLO is Hold , which takes into account factors such as growth and prof...